Motpoly Xr Capsule, Extended Release
Product Images NDC 73289-0063

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Motpoly Xr (NDC 73289-0063). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aucta Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Container-100mg (Container 100mg)

Motpoly XR 100 mg extended-release capsules label showing lacosamide as the active ingredient. The label includes dosage form and strength, directions for use, pharmacist attention note, and manufacturer information for Aucta Pharmaceuticals, Inc. It indicates a package size of 60 capsules and the oral route of administration.*

FDA Label Image

Container-150mg (Container 150mg)

Label for Motpoly XR extended-release capsules containing 150 mg lacosamide. The label includes storage instructions, a barcode, pharmacist warning about a Medication Guide, and dosing directions. It is manufactured for Aucta Pharmaceuticals, Inc. and the package contains 60 oral capsules.*

FDA Label Image

Container-200mg (Container 200mg)

Label for Motpoly XR 200 mg extended-release capsules containing lacosamide. The label includes the dosage strength, an extended-release capsule dosage form, and notes it is manufactured by Aucta Pharmaceuticals, Inc. It also states the package contains 60 capsules and provides storage instructions along with pharmacist and usage information.*

FDA Label Image

Chemical-structure (Lacosamide 01)

Chemical structure diagram of lacosamide, the active ingredient in MOTPOLY XR extended-release capsules. The structure shows characteristic functional groups and the arrangement of atoms specific to lacosamide.*

FDA Label Image

Fig-1 (Lacosamide 02)

A bar chart illustrating the median percent reduction in seizure frequency per 28 days from baseline to the maintenance phase by dose from three studies. The x-axis compares placebo and lacosamide doses (200 mg, 400 mg, 600 mg), and the y-axis shows seizure reduction percentages up to 45%. Each study shows higher median seizure reduction with lacosamide compared to placebo, with statistically significant differences marked.*

FDA Label Image

Fig-2 (Lacosamide 03)

A line chart labeled Figure 2 depicting the proportion of patients by responder rate for lacosamide and placebo groups across Studies 2, 3, and 4. The y-axis shows responder rate (%) ranging from -100% (worsening) to 100% (improvement), and the x-axis shows percent of patients from 100% to 0%. Four lines represent placebo and lacosamide at 200 mg/day, 400 mg/day, and 600 mg/day doses, illustrating patient response distributions.*

FDA Label Image

Professional-sample-carton (Professional Sample Carton)

Packaging label for Motpoly XR 100 mg extended-release capsules containing lacosamide. The label states the product is a professional sample, not for sale, with 14 capsules per package. The labeler is Aucta Pharmaceuticals, Inc. The label includes dosage form, strength, Rx only status, and cautions for physicians.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.